1-8 of 8
Jason Moffat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models

Open Access
Manja Friese-Hamim, Maria J. Ortiz Ruiz, Olga Bogatyrova, Marina Keil, Felix Rohdich, Beatrix Blume, Birgitta Leuthner, Frank Czauderna, Diane Hahn, Julia Jabs, Frank Jaehrling, Timo Heinrich, Roland Kellner, Katherine Chan, Amy H.Y. Tong, Dirk Wienke, Jason Moffat, Andree Blaukat, Frank T. Zenke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 159–173.
https://doi.org/10.1158/1535-7163.MCT-23-0102
Published: 01 February 2024
View article titled, Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Open the PDF for Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models in another window
Includes: Supplementary data
Journal Articles

Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma

Free
Stefan Custers, Laura Escudero, Yujin Suk, Dillon McKenna, William Gwynne, Iqra Chaudhry, Jeremy Chan, Andrew Quaile, Jason Moffat, Chitra Venugopal, Rafael Montenegro-Burke, Sheila Singh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C082.
https://doi.org/10.1158/1535-7163.TARG-23-C082
Published: 01 December 2023
View article titled, Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma
Journal Articles

Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma

Free
David Bakhshinyan, Stefan Custers, Ashley Adile, Kevin Brown, Maleeha Qazi, Chirayu Chokshi, Laura Escudero, Yujin Suk, Chitra Venugopal, Jason Moffat, Sheila Singh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A158.
https://doi.org/10.1158/1535-7163.TARG-23-A158
Published: 01 December 2023
View article titled, Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma
Journal Articles

Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma

Free
Sheila Singh, William Gwynne, Yujin Suk, Jeremy Chan, Andrew Qualie, Laura Escudero, Kevin Brown, Chitra Venugopal, Jason Moffat, Rafael Montenegro-Burke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C097.
https://doi.org/10.1158/1535-7163.TARG-23-C097
Published: 01 December 2023
View article titled, Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma
Journal Articles

Abstract PR12: A genome-wide shRNA screen reveals that inhibiting kinases potentiates the anti-breast cancer activity of fluvastatin

Free
Janice Pong, Aleksandra Pandyra, Carolyn Goard, Elke Ericson, Kevin Brown, Jarkko Ylanko, David Andrews, Corey Nislow, Jason Moffat, Linda Penn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR12.
https://doi.org/10.1158/1535-7163.PMS-PR12
Published: 01 May 2014
View article titled, Abstract PR12: A genome-wide shRNA screen reveals that inhibiting kinases potentiates the anti-breast cancer activity of fluvastatin
Journal Articles

Abstract PR01: Functional characterization of breast cancer using pooled lentivirus shRNA screens

Free
Richard Marcotte, Azin Sayad, Maliha Haider, Kevin Brown, Troy Ketela, Jason Moffat, Benjamin G. Neel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR01.
https://doi.org/10.1158/1535-7163.PMS-PR01
Published: 01 May 2014
View article titled, Abstract PR01: Functional characterization of breast cancer using pooled lentivirus shRNA screens
Journal Articles

Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Free
Craig D. Simpson, Rose Hurren, Neil MacLean, Yanina Eberhard, Troy Ketela, Jason Moffat, Aaron D. Schimmer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A22.
https://doi.org/10.1158/1535-7163.TARG-11-A22
Published: 12 November 2011
View article titled, Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.
Journal Articles

Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Free
Tabitha E. Wood, Shadi Dalili, Craig D. Simpson, Mahadeo A. Sukhai, Rose Hurren, Kika Anyiwe, Xinliang Mao, Fernando Suarez Saiz, Marcela Gronda, Yanina Eberhard, Neil MacLean, Troy Ketela, John C. Reed, Jason Moffat, Mark D. Minden, Robert A. Batey, Aaron D. Schimmer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 246–256.
https://doi.org/10.1158/1535-7163.MCT-09-0495
Published: 12 January 2010
View article titled, Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Open the PDF for Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands in another window
Includes: Supplementary data